CMBA
MRNA icon

C.M. Bidwell & Associates’s Moderna MRNA Stock Holding History

C.M. Bidwell & Associates’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$368K Buy
5,255
+695
+15% +$36K 0.15% 91
2026
Q1 		$232K Buy
+4,560
New +$213K 0.11% 124
2023
Q1 		– Sell
-1,108
Closed -$199K – 542
2022
Q4 		$199K Sell
1,108
-351
-24% -$57.4K 0.16% 125
2022
Q3 		$173K Sell
1,459
-241
-14% -$36.6K 0.14% 131
2022
Q2 		$243K Buy
+1,700
New +$243K 0.19% 89
2021
Q4 		– Sell
-739
Closed -$284K – 604
2021
Q3 		$284K Sell
739
-606
-45% -$223K 0.19% 97
2021
Q2 		$316K Sell
1,345
-205
-13% -$36.6K 0.21% 83
2021
Q1 		$203K Buy
1,550
+736
+90% +$107K 0.15% 129
2020
Q4 		$85K Buy
+814
New +$82.3K 0.07% 251

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

C.M. Bidwell & Associates's MRNA Position: Q2 2026 in Review

C.M. Bidwell & Associates increased its Moderna (MRNA) stake by 15% in Q2 2026, buying an estimated $36K and bringing the position to 5,255 shares worth $368K. The position accounts for 0.15% of the portfolio, ranked #91.

C.M. Bidwell & Associates first reported a position in MRNA in Q4 2020 and has held it in 9 quarters since. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • C.M. Bidwell & Associates held 5,255 shares of Moderna worth $368K as of Q2 2026.
  • C.M. Bidwell & Associates bought 695 Moderna shares in Q2 2026, an estimated $36K.
  • Moderna made up 0.15% of C.M. Bidwell & Associates's portfolio in Q2 2026, its #91 holding.
  • C.M. Bidwell & Associates first reported a position in Moderna in Q4 2020 and has held it in 9 quarters since.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2026, filed 11 Aug 2026.